通过阻断GluA2 AMPAR的内细胞分裂来治疗缺血性中风的治疗潜力
Yujiao Qin1, Qingye Zhu1, Zhixiang Yan2
1Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao 266021, China.
Journal of medicinal chemistry
|February 3, 2026
概括
一种新的合,P3LC7LC-P,通过稳定AMPA受体和增强神经保护,显示出治疗缺血性中风的希望. 这种化合物表现出更好的稳定性,并在中风模型中显著减少大脑损伤.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 急性缺血性中风是导致死亡和残疾的主要原因.
- 针对GluA2 AMPA受体子单元与BRAG2的相互作用,提供了一个潜在的治疗策略.
- 像Tat-GluA2-3Y这样的现有抑制剂在体内稳定性上有局限性.
研究的目的:
- 开发一种更稳定,更有效的治疗药物用于缺血性中风.
- 研究针对GluA2-BRAG2相互作用的新型接的神经保护潜力.
主要方法:
- 基于GluA2-3Y序列的聚合的设计和合成.
- 对BRAG的结合亲和力的评估2.2.
- 在缺氧-葡萄糖和谷氨酸诱导的神经毒性模型中评估神经保护.
- 测量血稳定性和半衰期的药理动力学研究.
- 在瞬态中脑动脉封闭 (tMCAO) 模型中进行体内疗效测试.
主要成果:
- 确定P3LC7LC-P作为一种具有高亲和度BRAG2结合的化合物.
- P3LC7LC-P在体外模型中显示出显著的神经保护作用.
- P3LC7LC-P表现出增强的血稳定性,半衰期超过372.7分钟.
- 在tMCAO模型中,P3LC7LC-P在8mg/kg的剂量下降了21.00%的脑梗塞.
结论:
- 杂质P3LC7LC-P是一种有前途的神经保护剂,用于缺血性中风.
- P3LC7LC-P克服了之前的抑制剂的稳定性限制.
- 进一步开发P3LC7LC-P可能会导致急性缺血性中风的新疗法.
相关概念视频
Receptor-mediated Endocytosis
111.0K
Overview
111.0K
Receptor-mediated Endocytosis
7.9K
Receptor-mediated endocytosis is when bulk amounts of specific molecules are imported into a cell after binding to cell surface receptors. The molecules bound to these receptors are taken into the cell through inward folding of the cell surface membrane, which is eventually pinched off into a vesicle within the cell. Structural proteins, such as clathrin, coat the budding vesicle.
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
7.9K
Endocytosis
12.6K
Eukaryotic cells acquire nutrients for growth and proliferation. Nutrients and other molecules that require degradation are internalized from the extracellular space by a process called endocytosis. The term ‘endocytosis' was first coined by Christian de Duve in 1963.
Endocytosis always begins with the plasma membrane enclosing an incoming molecule to form a transport vesicle which, in some cases, can be coated with a protein called ‘clathrin.' Endocytosed material is either...
Endocytosis always begins with the plasma membrane enclosing an incoming molecule to form a transport vesicle which, in some cases, can be coated with a protein called ‘clathrin.' Endocytosed material is either...
12.6K
Peptide Bonds
83.1K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
83.1K
The Early Endosome: Endocytosis of Transferrin
4.8K
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
4.8K
Therapeutic Index
6.8K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.8K


